Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Constance LamyHubert TissotMatthieu FaronEric BaudinLivia LamartinaCaroline PradonAbir Al GhuzlanSophie LeboulleuxJean-Luc PerfettiniAngelo PaciJulien HadouxSophie BroutinPublished in: The Journal of clinical endocrinology and metabolism (2022)
In this pilot study, we showed that serum succinate level is an oncometabolic biomarker that should be useful to identify SDHB-related carriers. Succinate levels are also a marker of metabolic tumor burden in patients with a metastatic PPGL and a potential marker of treatment response and follow-up.